Kentucky Retirement Systems owns $1.31 million in Hologic, Inc. (NASDAQ:HOLX)

Kentucky Retirement Systems reduced its position in shares of Hologic, Inc. (NASDAQ:HOLX – Free Report) by 1.3% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,586 shares of the medical equipment provider’s stock after selling 240 shares during the quarter. Kentucky Retirement Systems’ holdings in Hologic were worth $1,306,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in HOLX. PNC Financial Services Group Inc. raised its stake in Hologic by 0.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 31,933 shares of the medical equipment provider’s stock valued at $2,282,000 after acquiring an additional 288 shares during the period. Coldstream Capital Management Inc. purchased a new position in Hologic in the fourth quarter valued at approximately $305,000. DA Davidson & CO. acquired a new position in Hologic in the fourth quarter valued at approximately $204,000. Corient Private Wealth LLC boosted its stake in Hologic by 251.1% in the fourth quarter. Corient Private Wealth LLC now owns 51,106 shares of the medical equipment provider’s stock valued at $3,652,000 after buying an additional 36,550 shares during the period. Finally, SageView Advisory Group LLC purchased a new position in Hologic in the fourth quarter valued at about $289,000. Institutional investors and hedge funds own 94.73% of the company’s shares.

Hologic stock down 1.2%

NASDAQ:HOLX opened at $81.39 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32, and a current ratio of 3.99. The company has a market cap of $18.99 billion, a PE ratio of 41.53, a PEG ratio of 2.53 and a beta of 0.98. Hologic, Inc. it has a 52-week low of $64.02 and a 52-week high of $84.67. The stock has a 50-day simple moving average of $80.82 and a 200-day simple moving average of $77.12.

Hologic (NASDAQ:HOLX – Get Your Free Report ) last released its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. Hologic’s quarterly revenue was up 2.7% year over year. In the same period last year, the company earned $0.93 per share. On average, sell-side analysts expect that Hologic, Inc. to record 4.09 EPS for the current fiscal year.

Changes in Analyst Ratings

Several equities analysts have weighed in on HOLX shares. Needham & Company LLC reissued a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Tuesday, September 17th. Royal Bank of Canada reissued a “sector perform” rating and issued a $82.00 target price on shares of Hologic in a research note on Friday, August 16th. Evercore ISI boosted their price target on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Tuesday, July 30th. Stephens restated an “overweight” rating and issued a $92.00 target price on shares of Hologic in a report on Tuesday, July 30th. Finally, JPMorgan Chase & Co. boosted their target price on Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of “Moderate Buy” and a consensus price target of $87.60, based on data from MarketBeat.

Get the latest stock analysis on HOLX

Insider buying and selling at Hologic

In other Hologic news, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the transaction, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC’s website. In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the completion of the transaction, the insider now directly owns 10,476 shares in the company, valued at $858,927.24. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC’s website. Also, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the transaction, the insider now owns 3,735 shares of the company’s stock, valued at $310,415.85. The disclosure for this sale can be found here. Insiders have sold a total of 18,280 shares of company stock worth $1,469,973 over the last ninety days. 1.75% of shares are currently held by corporate insiders.

About Hologic

(Free Report)

Hologic, Inc develops, manufactures and supplies diagnostic products, medical imaging systems and surgical products for women’s health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgery and Skeletal Health. Offers Aptima molecular diagnostic tests to detect infectious microorganisms; Aptima viral load tests for hepatitis B virus, hepatitis C virus, human immunodeficiency virus, and human cytomegalovirus; Aptima Bacterial Vaginosis and Candida Vaginitis Tests for Vaginitis Diagnosis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 tests to detect SARS-CoV-2; ThinPrep System for cytology applications; and the rapid fetal fibronectin test that helps doctors assess the risk of preterm birth.

Featured stories

Get news and reviews for Hologic Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Hologic and related companies with MarketBeat.com’s FREE daily email newsletter.